Invivyd starts Phase 2 FLINTLOCK trial of VYD2311 for long COVID, post — vaccination syndrome
Invivyd launched FLINTLOCK, a Phase 2 trial of VYD2311 for Long COVID or post-vaccination syndrome. Safety and potential clinical benefit will be assessed versus placebo over 90 days in adults aged 18-65. Initial readout is expected in mid-2027; no results have been presented yet. Program expands VYD2311’s development